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Abstract
Aims/hypothesis The pancreas and hypothalamus are criti-
cal for maintaining nutrient and energy homeostasis, and
combined disorders in these organs account for the onset of
the metabolic syndrome. Activating transcription factor 3
(ATF3) is an adaptive response transcription factor. The phys-
iological role of ATF3 in the pancreas has been controversial,
and its role in the hypothalamus remains unknown. To eluci-
date the roles of ATF3 in these organs, we generated pancreas-
and hypothalamus-specific Atf3 knockout (PHT-Atf3-KO)
mice in this study.
Methods We crossed mice bearing floxed Atf3 alleles with
Pdx1-cre mice, in which cre is specifically expressed in the
pancreas and hypothalamus, and analysed metabolic
variables, pancreatic morphology, food intake, energy ex-
penditure and sympathetic activity in adipose tissue. We
also used a hypothalamic cell line to investigate the molec-
ular mechanism by which ATF3 regulates transcription of
the gene encoding agouti-related protein (Agrp).
Results Although PHT-Atf3-KO mice displayed better glu-
cose tolerance, neither plasma glucagon nor insulin level
was altered in these mice. However, these mice exhibited
higher insulin sensitivity, which was accompanied by a
leaner phenotype due to decreased food intake and increased
energy expenditure. We also observed decreased hypotha-
lamic Agrp expression in PHT-Atf3-KO mice. Importantly,
an increase in ATF3 levels is induced by fasting or low
glucose in the hypothalamus. We also showed that ATF3
interacts with forkhead box-containing protein, O subfamily
1 (FoxO1) on the Agrp promoter and activates Agrp
transcription.
Conclusions/interpretation Our results suggest that ATF3
plays an important role in the control of glucose and energy
metabolism by regulating Agrp.




ATF3 Activating transcription factor 3
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Introduction
Although its definition and aetiology remain controversial,
the metabolic syndrome is considered to be the combination
of type 2 diabetes, obesity, hyperlipidaemia and hyperten-
sion [1, 2]. Among these disorders, obesity is the most
fundamental factor for diagnosis because increased fat cells
and macrophages secrete inflammatory cytokines and in-
duce insulin resistance, which is a key feature of the meta-
bolic syndrome [3]. Obesity is caused by an imbalance
between energy intake and energy consumption, which is
also termed a failure of energy homeostasis. The most
important organ for regulating energy homeostasis is the
hypothalamus. The hypothalamus contains two distinct neu-
rone types: one secretes agouti-related protein (AGRP),
which increases food intake and reduces energy expendi-
ture, and the other secretes proopiomelanocortin, which de-
creases food intake and increases energy expenditure [4, 5].
Recent genetic studies have revealed that insulin signal-
ling in the hypothalamus is implicated in the regulation of
energy homeostasis. Dysregulation of insulin receptor sub-
strate 2 (IRS2) in the hypothalamus causes obesity and
diabetes [6, 7]. FoxO1, an isoform of forkhead box-
containing protein of the O subfamily, is a downstream
effector of insulin signalling and mediates various metabolic
functions of insulin [8]. We previously reported that hypo-
thalamic FoxO1 regulates Agrp transcription and plays an
important role in the regulation of food intake and energy
expenditure [9, 10]. FoxO1 directly binds to the Agrp pro-
moter, leading to the recruitment of coactivator CBP/P300
and activating Agrp transcription [9]. Mice that produced
constitutively active FoxO1 specifically in the hypothala-
mus developed obesity and insulin resistance due to in-
creased food intake and reduced energy expenditure [10].
Activating transcription factor 3 (ATF3) is a member of
the ATF/CREB family of transcription factors. Atf3 gene
expression is induced by a variety of extracellular signals,
including cytokines, chemokines, growth factors, hormones,
hypoxia, DNA damage, endoplasmic reticulum stress and
nutrient deprivation. Although Atf3 has long been
recognised as a stress-response gene, recent cumulative
evidence has suggested that ATF3 is involved in more
general adaptive responses, such as environmental, emo-
tional and nutritional alterations [11–13]. ATF3 is found in
various cell types, and its disorders have been suggested to
associate with inflammatory diseases, immune diseases and
cancer [14]. We also previously reported that ATF3 is highly
expressed in the vascular endothelial cells of human athero-
sclerotic lesions and is centrally involved in endothelial cell
death, which might be associated with atherogenesis [15, 16].
To date, a number of studies have been conducted to
elucidate the physiological roles of ATF3 in the pancreas.
However, there are critical discrepancies in those studies,
and the role of ATF3 in the pancreas is still controversial
[17–21]. With respect to the role of ATF3 in the brain, it has
been reported that ATF3 is expressed in cortical and hippo-
campal neurones and protects against neuronal cell death,
which reduces brain damage after cerebral ischaemia [22].
ATF3 in the nucleus accumbens is reportedly critical for the
regulation of emotional behaviour [13]. In contrast, al-
though genome-wide profiling of fetal hypothalamic
neurones has revealed that Atf3 is highly expressed in the
murine hypothalamus [23], its physiological role in the
hypothalamus remains unknown. To elucidate these impor-
tant points, we analysed knockout mice in which the ATF3
level was reduced in the pancreas and hypothalamus.
In the present study, we make two important suggestions.
First, the physiological function of ATF3 in the pancreas
appears to be less significant than previously predicted.
Second, ATF3 has a novel, important function in the hypo-
thalamus: hypothalamic ATF3 regulates glucose and energy
metabolism by activating Agrp transcription.
Methods
DNA constructs, siRNA, and adenoviruses Flag-mAtf3 was
generated by PCR and subcloned into pcDNA3. PiGENE
mU6 Puro-shAtf3 was purchased from iGENE (Tokyo, Ja-
pan). pGL3-Agrp and pCMV5-Flag-FoxO1 have been pre-
viously described [9, 10]. The FoxO1-specific small
interfering RNA (siRNA) sequence is 5′-ACG GAG GAT
TGA ACC AGT ATA-3′. We have previously described
Ad-Atf3 [24].
Cell culture, transfection, adenovirus infection and luciferase
assays Hypothalamic N-41 cells (Cosmo Bio, Tokyo, Japan)
were maintained in high-glucose DMEM supplemented with
10% FBS. Transient transfection was performed using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Adenovirus in-
fection was performed using a standard protocol at a multi-
plicity of infection (MOI) of 50. For luciferase assays, the cells
were cotransfected with a reporter plasmid and the indicated
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amount of expression vectors. The total amount of DNAwas
adjusted to 0.8 μg/well with the addition of each correspond-
ing empty vector. PRL-TK-Luc plasmid (0.1 μg) was used as
an internal control.
RNA isolation and real-time RT-PCR Total RNAs were
isolated from cells or tissues using RNAiso Plus (Takara,
Shiga, Japan), and cDNAs were made using the Improm II
Reverse Transcription System (Promega, Madison, WI,
USA). cDNAs generated (1 μg) were subjected to real-
time PCR using the LightCycler system and LightCycler
480 SYBR Green I (Roche, Indianapolis, IN, USA). The
PCR conditions were 5 min at 95°C, followed by 40 cycles
at 95°C for 10 s, 60°C for 10 s and 72°C for 10 s. The
primer sequences are available upon request.
Western blot analyses Proteins from cell lysates or tissue
extracts were separated by SDS-PAGE, transferred to nitro-
cellulose membranes (Pall Gelman Laboratory, Ann Arbor,
MI, USA) and blotted with antibodies. Monoclonal anti-
bodies against ATF3 were generated by immunising
BALB/c mice with synthetic peptides derived from the
carboxyl-terminal end of human/mouse ATF3, and hybrid-
oma cell lines were established by fusing splenocytes with
Sp2/0-Ag14 myeloma cells. Immunoreactive proteins were
assessed by LAS-4000 Image analyser (Fuji Film, Tokyo,
Japan) and densitometry using ImageJ software (NIH,
Maryland, MD, USA).
Chromatin immunoprecipitation assays We performed
chromatin immunoprecipitation assays in N-41 cells using
the SimpleChIPM Enzymatic Chromatin IP Kit (Cell Signal-
ing, Danvers, MA, USA) according to the manufacturer’s in-
structions. We used the following primers: 5′-CCT GAAAGC
TTT GTC CTC TGA AGC-3′ and 5′-GCA GAA CCT AGG
GAT GGG TCA TGC-3′, corresponding to −401 to −378
and −8 to +16 of the mouse Agrp gene.
Animals and analytical procedures Pancreas- and
hypothalamus-specific Atf3 knockout (PHT-Atf3-KO) mice
were generated by crossing Pdx1-cre mice [25] with Atf3-
flox mice [26]. Genotyping was performed by PCR. To
detect the Atf3-deleted allele, we used the following primers;
forward 5′-ACT GGG GCA AAG AAA CAT ACC-3′ and
reverse 5′-TAC CTC AGA TTT CCC TCA AAC-3′.
Mice were housed in individual cages in a temperature-
controlled facility with a 12 h light/12 h dark cycle. All animal
care and experimental procedures were approved by the Institu-
tional Animal Care and Experimentation Committee at Gunma
University. Mice were maintained on a 129/J × C57BL/6J
background, and their littermates were used as controls.
Blood glucose levels were measured using a glucometer
(Sanwa Kagaku, Nagoya, Japan). Plasma glucagon and
insulin levels were measured by RIA (Millipore, Billerica,
MA, USA) and ELISA (Shibayagi, Gunma, Japan), respec-
tively. Plasma catecholamine levels were measured by
ELISA (Cusabio, Hubei, China). For the glucose tolerance
test (GTT), mice were subjected to an overnight fast
followed by i.p. glucose injection (1.0 g/kg). For the insulin
tolerance test (ITT), human insulin (Eli Lilly, Kobe, Japan)
was injected (0.75 U/kg i.p.) to randomly fed mice. To test
AKT phosphorylation, 24 h-fasted mice were injected (i.p.)
with 5 U/kg of insulin. Fifteen minutes later, liver and
skeletal muscle (SM) samples were subjected to western
blot analysis using anti-phospho AKT (Ser473) or AKT
antibody (Cell Signaling). Body weight was measured
weekly, and food intake was measured daily in the dark
(18:00–06:00 hours) or light (06:00–18:00 hours) phase
using manual feeding hoppers. For adiposity measurement,
CT was performed using a LaTheta LCT-200 (Hitachi-
Aloka, Tokyo, Japan). Islets isolated from mice as described
previously [27] were preincubated in Krebs–Ringer solution
containing 2.8 mmol/l glucose for 15 min, and then exposed
to 0.5, 10, and 25 mmol/l glucose for 1 h at 37°C. At the end
of incubation, the supernatant fraction was assayed for glu-
cagon or insulin.
Immunohistochemistry Fixed-frozen sections of mouse
pancreas or hypothalamus were subjected to immunohis-
tochemistry with anti-ATF3 (H-90; Santa Cruz, Delaware,
CA, USA), anti-glucagon (Sigma, St Louis, MO, USA),
anti-insulin (Dako, Carpinteria, CA, USA), anti-Ki67
(NovoCastra, Newcastle, UK), anti-caspase3 (Promega)
or anti-AGRP antibody (Santa Cruz). We visualised im-
mune complexes with FITC- or cyanin 3 (Cy3)-conjugated
secondary antibodies. To quantify the percentage area of
alpha cells or beta cells in relation to the pancreas, we
measured the area of glucagon or insulin staining using
BZ-9000 (Keyence, Osaka, Japan) and NIS-Elements
(Nikon, Tokyo, Japan). We scored at least ten sections
for each mouse, and six mice for each genotype. For
uncoupling protein 1 (UCP1) staining, brown adipose
tissue (BAT), inguinal white adipose tissue (iWAT) and
epididymal white adipose tissue (eWAT) were dissected
and the paraffin-sectioned slides were subjected to immu-
nohistochemistry with anti-UCP1 antibody (Abcam, Cam-
bridge, MA, USA). For c-fos staining, paraffin-sectioned
hypothalamuses were immunostained with c-fos antibody
(Santa Cruz).
Energy metabolism Measurements of oxygen consumption
and carbon dioxide production were performed individu-
ally on 8-month-old mice using an Oxymax apparatus
(Columbus Instruments, Columbus, OH, USA) with free
access to food and water. Total oxygen consumption was
calculated as the accumulated oxygen uptake for each
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O2 . Heat generation was calculated as caloric
value (CV) × V
:
O2, where CV=3.815+1.232 × RER. Loco-
motor activity was measured using the ACTIMO-100
(BioResearch, Tokyo, Japan).
Statistical analyses Data are expressed as mean ± SEM.
Statistical significance was assessed by the Student’s t test
and/or one-way ANOVA using the Prism program.
Results
Tissue-specific ablation of ATF3 in the pancreas and hypo-
thalamus of PHT-Atf3-KO mice To date, it has been contro-
versial whether the physiological role of ATF3 in the
pancreas is beneficial or detrimental to the regulation of
glucose metabolism. Moreover, the role of ATF3 in the
hypothalamus remains totally unknown. To clarify these
important issues, we generated PHT-Atf3-KO mice by cross-
ing mice bearing floxed Atf3 alleles [26] with Pdx1-cre mice
[25]. Although Pdx1-cre mice have been widely used to
generate pancreas-specific gene knockout mice, the cre
transgene is reportedly expressed in both the hypothalamus
and the pancreas [10, 28]. Genotyping of DNA extracted
from various organs showed that Cremediated excision oc-
curred only in the islets and hypothalamus, and not in the
other organs in PHT-Atf3-KO mice (Fig. 1a). To address the
knockout efficiency of ATF3 at the protein level, we
performed western blotting with anti-ATF3 antibody. ATF3
protein levels were reduced by 65% in the islets and by 75%
in the hypothalamus of PHT-Atf3-KO mice compared with
control mice, as quantified using densitometry (Fig. 1b, c).
Immunohistochemical analyses also revealed that the ATF3
level was reduced in pancreatic alpha cells and beta cells
(Fig. 2a), and ATF3 as well as AGRP levels were reduced in
the hypothalamic area of PHT-Atf3-KO mice (Fig. 2b). The
reduction of Agrp expression will be discussed below.
PHT-Atf3-KO mice have lower blood glucose levels and
better glucose tolerance than control mice To investigate
the effects of ATF3 ablation, we first examined blood glu-
cose levels in PHT-Atf3-KO mice. Glucose levels after both
fasting and random feeding were significantly lower in these
mice than in the control mice (Fig. 3a, b). PHT-Atf3-KO
mice have significantly better glucose tolerance than control
mice at 2, 4 and 8 months of age (Fig. 3c, electronic
supplementary material [ESM] Fig. 1a, b). Because previous
reports have suggested that ATF3 plays an important role in
pancreatic alpha cells or beta cells by regulating glucagon or
insulin gene transcription [19, 20], we predicted that levels
of plasma glucagon or insulin might be altered in PHT-Atf3-
KO mice. However, plasma glucagon and insulin levels
were comparable between PHT-Atf3-KO and control mice
(Fig. 3d–g). Furthermore, plasma glucagon levels were
unchanged even under severely hypoglycaemic conditions
in PHT-Atf3-KO mice (ESM Fig. 2a).
PHT-Atf3-KO mice have normal islet function and
morphology We next assessed the expression levels of glu-
cagon and insulin 1 in islets isolated from PHT-Atf3-KO
mice. Both the levels of Gcg and Ins1 mRNAs did not differ
between PHT-Atf3-KO and control mice (Fig. 3h, i). We also
found that there was no change in the ability to secrete
glucagon or insulin in response to glucose in these mice
(Fig. 3j, k). Because the transgenic mice overexpressing
ATF3 under the control of the Pdx1 promoter or the Ins1
promoter had a reduced beta cell mass [18, 21], we also
assessed beta and alpha cell mass in PHT-Atf3-KO mice.
The percentage area of alpha cells and beta cells was
unchanged in PHT-Atf3-KO mice (ESM Fig. 2b–d).
Fig. 1 Tissue-specific ablation of ATF3 in the pancreatic islets and
hypothalamus of PHT-Atf3-KO mice. (a) Genotyping of DNA isolated
from the pancreatic islets, liver, kidney, muscle, hypothalamus and
cerebral cortex of wild-type (WT) and PHT-Atf3-KO (KO) mice for
multiplex detection of WT and floxed alleles (top part), or for single
detection of the deleted allele (bottom part). Pancreatic islets (b) and
hypothalamus (c) isolated from PHT-Atf3-KO and control mice after
12 h of fasting were used for western blotting with anti-ATF3 mono-
clonal antibody. The results were normalised using α-tubulin. Densi-
tometric analyses of the western blots are shown in the graphs on the
right. Data are mean ± SEM. **p<0.01
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Furthermore, there was no change in islet cell proliferation
or apoptosis in these mice (ESM Fig. 2e, f). Taken together,
these results indicate that the function and the morphology
of pancreatic islets are normal in PHT-Atf3-KO mice.
PHT-Atf3-KO mice exhibit high insulin sensitivity and lean
phenotype accompanied by reduced food intake To eluci-
date the reason for better glucose tolerance in PHT-Atf3-KO
mice, despite normal islet function and morphology, we
examined insulin sensitivity in these mice. The ITT revealed
that PHT-Atf3-KO mice had significantly higher insulin
sensitivity at 2, 4 and 8 months of age (Fig. 4a, ESM
Fig. 3a, b). We also confirmed the higher insulin sensitivity
by evaluating insulin-induced AKT phosphorylation in liver
and SM, which were clearly elevated in PHT-Atf3-KO mice
(Fig. 4b). Because PHT-Atf3-KO mice showed lower blood
glucose levels predominantly during the later period of the
ITT, we asked whether the counterregulatory response to
hypoglycaemia was hampered in these mice. However, both
c-fos activation in the hypothalamus and circulating cate-
cholamine levels in response to hypoglycaemia were com-
parable between PHT-Atf3-KO and control mice, indicating
that the counterregulatory response is normal in these mice
(ESM Fig. 3c, d).
Importantly, we observed that PHT-Atf3-KO mice were
significantly leaner than control mice at all these ages
(Fig. 4c). Consistent with these results, the weights of in-
guinal iWAT and eWAT were significantly reduced in PHT-
Atf3-KO mice (Fig. 4d, ESM Fig. 3e). Adiposity measured
by CT scanning was also decreased in PHT-Atf3-KO mice
(Fig. 4e), while lean body mass and body length were
comparable (Fig. 4f, ESM Fig. 3f). Next, we investigated
the reason for the lean phenotype in PHT-Atf3-KO mice by
measuring food intake. Daily food intake was significantly
reduced in PHT-Atf3-KO mice compared with control mice
(Fig. 4g). Furthermore, food intake in both the dark and light
phases was comparably reduced in PHT-Atf3-KO mice
(Fig. 4h, ESM Fig. 3g).
We also tested whether these mice were resistant to high-
fat diet (HFD) induced metabolic disorders. Body weight
was significantly lower and glucose tolerance and insulin
tolerance tended to be better in PHT-Atf3-KO mice than in
control mice under HFD conditions (Fig. 4i–k). The milder
phenotype seen in HFD conditions compared with the
Fig. 2 Deficiency of ATF3
expression in pancreatic alpha
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regular diet suggested that HFD may have attenuated the
beneficial effects of ATF3 deficiency.
PHT-Atf3-KO mice have increased energy expenditure due
to higher sympathetic tone and WAT to BAT conversion As
another reason for the lean phenotype, we observed that
oxygen consumption was significantly increased in PHT-
Atf3-KO mice during both the light and dark phases
(Fig. 5a). Accumulated oxygen consumption during the
light or dark phase and 24 h oxygen consumption were also
significantly increased (Fig. 5b). Carbon dioxide produc-
tion, average RER and heat production were significantly
increased in PHT-Atf3-KO mice (ESM Fig. 4a–c). In com-
parison, locomotor activities during these periods were
unchanged in these mice (Fig. 5c). These results suggested
that the increased energy expenditure was accounted for by
increased basal metabolism rather than increased physical
activity in PHT-Atf3-KO mice.
To elucidate the molecular mechanism by which basal
metabolism was increased in PHT-Atf3-KO mice, we first
investigated the expression levels of mitochondrial genes in
BAT, eWAT and SM. Ppargc1a in BAT and eWAT and Ucp1
in BAT were significantly increased in PHT-Atf3-KO mice
(Fig. 5d, e). We then asked whether sympathetic tone was
increased in these mice. As we expected, the expression
levels of adrenergic receptors were increased in BAT, eWAT
and SM of PHT-Atf3-KO mice (ESM Fig. 4d–f). Further-
more, PHT-Atf3-KO mice maintained a higher body temper-
ature during cold exposure (Fig. 5f), which is consistent
with the idea that PHT-Atf3-KO mice have higher sympa-
thetic tone than control mice.
More strikingly, histological analyses using fat tissues
revealed that UCP1-expressing adipocytes were increased
after cold exposure in the iWAT but not the eWAT of PHT-
Atf3-KO mice (Fig. 5g). We confirmed these results by
quantitative RT-PCR and found that Ucp1 levels were dra-
matically increased in the iWAT of PHT-Atf3-KO mice after
cold exposure (Fig. 5h). Prdm16, a key regulator of subcu-
taneous WAT to BAT conversion [29, 30], tended to increase
in PHT-Atf3-KO mice (Fig. 5i). These results indicated that
PHT-Atf3-KO mice have high sympathetic activity in adi-
pose tissues, causing a ‘browning’ of white adipose tissues,
a rise in whole-body energy expenditure and subsequent
weight loss.
Fig. 3 Reduced blood glucose and improved glucose tolerance in
PHT-Atf3-KO mice without alterations in plasma glucagon or insulin.
Fasted (a) and randomly fed (b) blood glucose levels in PHT-Atf3-KO
(n=14) and control (n=11) mice at 4 months of age. (c) GTTs (i.p.) in
PHT-Atf3-KO (n=14) and control (n=11) mice at 4 months of age.
White circles, control mice; black circles, PHT-Atf3-KO mice. AUC
data for the results are also shown. Fasted and randomly fed plasma
glucagon (d,e) and plasma insulin (f,g) levels in PHT-Atf3-KO (n=10)
and control (n=10) mice at 4 months of age. mRNA levels of Gcg (h)
and Ins1 (i) in the islets of PHT-Atf3-KO (n=4) and control (n=4) mice
by real-time RT-PCR at 3 months of age. Glucagon (j) and insulin (k)
secretion from the islets of PHT-Atf3-KO mice in response to changes
in glucose concentration. The results are presented as the percentage of
basal glucagon or insulin release in the control mice. Data are mean ±
SEM. *p<0.05, **p<0.01
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Correlative expression patterns of ATF3 and AGRP were
observed in N-41 cells and mouse hypothalamus Because
food intake was reduced in PHT-Atf3-KO mice, we assessed
the expression levels of appetite-related neuropeptides in the
hypothalamus and found that Agrp mRNAwas significantly
lower in PHT-Atf3-KO mice than in control mice (Fig. 6a),
which is consistent with the reduced food intake in these
mice (Fig. 4g, h). Neither Npy, Pomc nor Hcrt (orexin) was
changed in these mice (Fig. 6a).
We then investigated the relationship between ATF3 and
AGRP more precisely using the hypothalamic N-41 cell line.
Atf3mRNA levels in N-41 cells were increased by low glucose
and reduced by high glucose, which is similar to the pattern of
Agrp mRNA levels (Fig. 6b). Because an increase in AGRP
levels is induced by fasting [9, 31], we next investigated Atf3
mRNA levels in the hypothalamus of wild-type mice under
various fasting conditions. Atf3 mRNA levels were increased
by fasting in a time-dependent manner that resembled the
pattern of Agrp expression (Fig. 6c). We also confirmed the
fasting-induced increase in ATF3 protein by western blotting
(Fig. 6d). Fasting Agrp expression was significantly reduced in
the hypothalamus of PHT-Atf3-KO mice compared with con-
trol mice (ESM Fig. 5a). These correlative observations
suggested that ATF3 may regulate Agrp transcription.
Fig. 4 Higher insulin sensitivity and lean phenotype associated with
decreased food intake in PHT-Atf3-KO mice. (a) ITTs in PHT-Atf3-KO
(n=18) and control (n=12) mice at 4 months of age. Results are shown
by absolute value and decremental area over the curve (AOC). (b)
AKT phosphorylation in liver and SM of PHT-Atf3-KO and control
mice at 4 months (n=3 for each group). (c) Body weights of PHT-Atf3-
KO at 2 months (n=46 control mice, n=54 KO mice), 4 months (n=23
control mice, n=32 KO mice) and 8 months (n=19 control mice, n=30
KO mice) of age. (d) Fat weights of PHT-Atf3-KO and control mice at
8 months (n=4 for each group). (e) Visceral and subcutaneous fat mass
were measured in PHT-Atf3-KO and control mice (n=4 for each
group). Data represent percentages of body mass. (f) Lean body mass
of PHT-Atf3-KO and control mice at 3 months of age (n=4 for each
group). (g) Daily food intake in PHT-Atf3-KO and control mice (n=12
for each group). (h) Food intake during the dark and light phases in
PHT-Atf3-KO (n=6) and control (n=7) mice at 7 months. Body weight
(i), GTTs (j) and ITTs (k) in PHT-Atf3-KO and control mice fed an
HFD starting at 4 weeks of age (n=4 for each group). Data are mean ±
SEM. *p<0.05, **p<0.01
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ATF3 regulates Agrp transcription by interacting with
FoxO1 on the Agrp promoter To test whether ATF3 regu-
lates Agrp transcription, we first conducted luciferase assays
using the mouse Agrp promoter. When we cotransfected
HEK293 cells or N-41 cells with Agrp promoter-driven
luciferase vector and ATF3 expression vector, luciferase
activity was increased by ATF3 expression in a dose-
dependent manner, indicating that ATF3 regulates Agrp
promoter activity (Fig. 6e).
We and others have previously reported that transcription
factor FoxO1 translocates to the nucleus and becomes active
in hypothalamic neurones under fasting conditions [9, 32],
and that FoxO1 directly binds to the Agrp promoter and
regulates Agrp transcription [9, 10]. Because the Agrp pro-
moter (−401 to +16) used in the luciferase assays does not
contain an ATF/CRE site but contains FoxO1 binding sites
(−363 to −319 and −130 to −86), we predicted that ATF3 may
regulateAgrp promoter activity by interacting with FoxO1. To
test this hypothesis, we performed a co-immunoprecipitation
assay in HEK293 cells cotransfected with ATF3 and
FoxO1. HA-tagged FoxO1 co-immunoprecipitated with
Flag-tagged ATF3, and conversely HA-tagged ATF3 co-
immunoprecipitated with Flag-tagged FoxO1 (Fig. 6f), indi-
cating that ATF3 interacts with FoxO1 in intact cells. Next, we
tested whether the interaction between ATF3 and FoxO1 was
occurring on the Agrp promoter. Chromatin immunoprecipi-
tation assay revealed that ATF3 bound to the Agrp promoter,
including two FoxO1-binding sites, when FoxO1 was
overexpressed (Fig. 6g). These results suggest that ATF3 is
recruited to the Agrp promoter through an interaction with
FoxO1.
ATF3 and FoxO1 are reciprocally required to activate Agrp
transcription To investigate the roles of ATF3 and FoxO1 in
the regulation of Agrp transcription, we measured Agrp pro-
moter activity in HEK293 cells cotransfected with ATF3 and
FoxO1. Coexpression of ATF3 increased FoxO1-induced
Agrp promoter activity, while coexpression of FoxO1 in-
creased ATF3-induced Agrp promoter activity in a dose-
dependent manner (ESM Fig. 5b, c), indicating synergistic
activation of the Agrp promoter by ATF3 and FoxO1.
Next, we asked whether inhibiting FoxO1 or ATF3 would
affect ATF3-induced or FoxO1-induced Agrp promoter activ-
ity, respectively. FoxO1 siRNA significantly reduced ATF3-
Fig. 5 Increased energy
expenditure due to higher
sympathetic tone and




oxygen consumption (b) and
locomotor activity (c) in
PHT-Atf3-KO (n=9) and control
(n=8) mice at 8 months of age.
mRNAs levels of Ppargc1a
(d) and Ucp1 (e) in BAT, eWAT
and SM of PHT-Atf3-KO and
control mice at 3 months of age
(n=4 for each group); ND, not
detected. (f) Rectal temperature
after cold exposure at 4°C for the
indicated periods (n=4 for each
group). UCP1 immunostaining
(g) and mRNA levels of Ucp1
(h) and Prdm16 (i) in
BAT, iWAT and eWAT of
PHT-Atf3-KO and control mice
after 3 days of cold exposure at
4°C (n=4 for each group). White
circles, control littermates; black
circles, PHT-Atf3-KO mice.
Scale bar: 10 μM. Data are mean
± SEM. *p<0.05; **p<0.01.
ND, no data
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induced Agrp-promoter activity in a dose-dependent manner,
while Atf3 small hairpin RNA (shRNA) partly suppressed
FoxO1-induced Agrp promoter activity (ESM Fig. 5d, e).
Furthermore, inhibition of either ATF3 or FoxO1 suppressed
low glucose-induced Agrp expression in N-41 cells (Fig. 6h).
These results demonstrated that ATF3 and FoxO1 are recip-
rocally required to activate Agrp transcription.
Discussion
Regarding double-tissue-specific knockout mice, gene abla-
tion in one tissue may affect the phenotype resulting from
gene ablation in another tissue. However, considering that
metabolic syndrome is a combined disorder involving both
the hypothalamus and the pancreas, the analyses of PHT-Atf3-
KO mice should provide more practical insights into the
relationship between ATF3 and the metabolic syndrome. In-
deed, hypothalamus- and pancreas-specific IRS2 knockout
mice have been used to determine the significance of com-
bined IRS2 dysfunction in both the hypothalamus and the
pancreas for the development of obesity and diabetes [6, 7].
There are several contradictions in the published litera-
ture regarding the physiological role of ATF3 in the pancre-
as, and the critical issue of whether pancreatic ATF3 is
beneficial or detrimental to the regulation of glucose
Fig. 6 ATF3 regulates Agrp transcription by interacting with FoxO1
on the Agrp promoter. (a) mRNA levels of Agrp, Npy, Pomc and Hcrt
in the hypothalamus after 24 h of fasting at 8 months of age (n=4 for
each group). (b) mRNA levels of Atf3 and Agrp in N-41 cells treated
with low glucose (LG) or high glucose (HG). (c) mRNA levels of Atf3
and Agrp in the hypothalamus of wild-type mice after fasting for the
periods indicated. (d) Hypothalamic ATF3 protein levels in wild-type
mice after fasting or refeeding for the periods indicated. (e) Agrp
promoter (−401 to +16)-driven luciferase (Luc) activities in HEK293
or N-41 cells transfected with ATF3 at the indicated amount of DNA.
(f) Co-IP of ATF3 and FoxO1 in HEK293 cells cotransfected with
ATF3 and FoxO1. HA-FoxO1 or HA-ATF3 was detected in the IP with
Flag-ATF3 or Flag-FoxO1, respectively; TCL, total cell lysate. (g) The
promoter region of the mouse Agrp gene. The square indicates the
forkhead response element. Arrows indicate the primers used for PCR.
Chromatin immunoprecipitation assays using indicated antibodies in
N-41 cells cotransfected with ATF3 and FoxO1. (h) mRNA levels of
Atf3 and Agrp in N-41 cells transfected with shAtf3 or FoxO1 siRNA.
Data are mean ± SEM. *p<0.05, **p<0.01. IB, immunoblot; IP,
immunoprecipitation
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homeostasis still remain unsolved [17]. The observations in
this study—normal plasma glucagon and insulin levels
(Fig. 3d–g), unchanged glucose-responsive glucagon and
insulin secretion (Fig. 3j, k), and normal alpha and beta cell
mass (ESM Fig. 2b–d) in PHT-Atf3-KO mice—suggested
that the physiological role of ATF3 in the pancreas may be
less significant than previously predicted, although the low-
er knockout efficiency of ATF3 in the pancreas (Fig. 1b)
should also be considered.
Despite the unchanged islet cell morphology and func-
tion, we observed a significant decrease in blood glucose
level and better glucose tolerance in PHT-Atf3-KO mice
compared with wild-type mice (Fig. 3a–c). Therefore, we
next focused on the lean phenotype and higher insulin
sensitivity in these mice (Fig. 4a–e). We observed that
PHT-Atf3-KO mice exhibited reduced food intake, which
was associated with reduced Agrp expression in the hypo-
thalamus (Fig. 4g, h, 6a). Although Agrp knockout mice
were originally reported to have normal food intake, body
weight and body composition [33], these mice are known to
show reduced body weight and adiposity after 6 months of
age [34]. Furthermore, postembryonic ablation of AGRP
neurones leads to a lean phenotype due to decreased food
intake and increased Ucp1 levels in BAT [35]. We also
observed that PHT-Atf3-KO mice have increased energy
expenditure, which is associated with increased Ppargc1a
and Ucp1 expression and increased sympathetic tone in
adipose tissues (Fig. 5a–i). We further elucidated the molec-
ular mechanism underlying these results: hypothalamic
ATF3 regulates Agrp transcription by interacting with
FoxO1. To our knowledge, all of the findings presented here
regarding the role of ATF3 in the hypothalamus are novel.
The limitation of this study is the lack of a pair-feeding
experiment, so it is unclear to what extent the phenotype of
PHT-Atf3-KO mice occurred secondary to reduced food
intake. However, because the oxygen consumption without
normalisation by body weight was still significantly in-
creased in these mice (ESM Fig. 4g, h), higher energy
expenditure was not simply due to the reduced food intake
or reduced body weight. Another important finding in this
study was the induction of Atf3 expression by low glucose
or fasting in a hypothalamic cell line or mouse hypothala-
mus (Fig. 6b–d). Because ATF3 is an adaptive response
gene [14], hypothalamic ATF3 level is probably regulated
by nutrient status. Additional study will be needed to clarify
the mechanism that determines how changes in nutrient
status regulate Atf3 expression in the hypothalamus.
Considering that ATF3 works as a transcriptional repres-
sor rather than an activator in most cell types [36] and that
FoxO1 binds to the Pomc promoter and inhibits its promoter
activity [9], it can be predicted that ATF3 suppresses Pomc
gene transcription, even though the level of Pomc mRNA
was unaltered in PHT-Atf3-KO mice compared with control
mice (Fig. 6a). To test this hypothesis, we performed lucif-
erase assays using the Pomc promoter, including the FoxO1
binding site [9]. However, in contrast to the Agrp promoter,
ATF3 did not affect Pomc promoter activity (data not
shown). Therefore, hypothalamic ATF3 regulates food in-
take and energy expenditure by upregulating Agrp transcrip-
tion rather than by downregulating Pomc transcription.
In the present study, we demonstrated that a reduction of
ATF3 in the hypothalamus leads to a lean phenotype, higher
insulin sensitivity and better glucose tolerance. Hypotha-
lamic ATF3 may be a useful target for the development of
a new strategy to treat or prevent obesity-based metabolic
syndrome.
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